Fibrilação atrial em paciente portador de cardiomiopatia hipertrófica e o uso de anticoagulantes orais:Relato de caso.

Sarah Alves Gandra, Flávio Fonseca Gonçalves, Álcio Antunes Amariz, Renato Amorim Carvalho, Rita de Cássia Oliveira Araújo, Rodrigo Lopes Malveira, André Luís Nobre, Renata de Carvalho Bicalho

Resumo

A Cardiomiopatia Hipertrófica (CMH) é uma doença autossômica dominante que atinge cerca de 0,2% da população geral. É caracterizada por hipertrofia ven­tricular esquerda assimétrica associada a uma câmara hiperdinâmica e não dilatada, na ausência de qualquer outro processo orgânico capaz de produzir alterações semelhantes. A CMH é um fator de risco para o desenvolvimento de fibrilação atrial a qual predispõe ao Acidente vascular encefálico (AVE). Em casos de FA persistente, na maioria das vezes, temos que considerar a anticoagulação oral, com controle clínico e laboratorial rigorosos. Estes fármacos também devem ser utilizados antes, durante e depois de cardioversão elétrica ou química, conforme recomendação internacional. O presente relato mostra o caso de uma paciente com o diagnóstico de miocardiopatia hipertrófica, com presença de fibrilação atrial crônica que evoluiu com acidente vascular encefálico isquêmico e posteriormente com acidente vascular encefálico hemorrágico.

 

Palavras-chave

Cardiomiopatia Hipertrófica; Fibrilação atrial; Acidente vascular encefálico; Anticoagulantes;

Texto completo:

Texto Completo

Referências

Arteaga E, Ianni BM, Fernandes F, Mady C. Benign outcome in a long-term follow-up of patients with hypertrophic cardiomyopathy in Brazil. Am Heart J.2005;149:1099-105.

Albanesi Fº FM. Cardiomiopatia hipertrófica. Estudo evolutivo de amostra acompanhada na cidade do Rio de Janeiro. [Tese de Livre-Docência]. Rio de Janeiro: Universidade do Estado do Rio de Janeiro; 1999.

Bungard TJ, Ackman ML, Ho G, Tsuyuki RT. Adequacy of anticoagulation

in patients with atrial fibrillation coming to a hospital. Pharmacotherapy.

;20(9):1060-5.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et

al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin

in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.

Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized

Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly.

identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-6.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al;

AVERROES Steering Committee and Investigators. Apixaban in patients

with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.

Diretrizes Brasileiras De antiagregantes Plaquetários e anticoagulantes em cardiologia, Sociedade Brasileira de Cardiologia Volume 101, Nº 3, Supl. 3, Setembro 2013.

European Society of Cardiology (ECS) Executive Committee; ESC Writing Committee. Practice Guidelines for the management of artrial fibrillation 2010. Eur Heart J 2010; 31:2369–2429.

Fattori R, Biagini E, Lorenzini M, Buttazzi K, Lovato L, Rapezzi C. Significance of magnetic resonance imaging in apical hypertro¬phic cardiomyopathy. Am J Cardiol. 2010; 105(11):1592-6.

Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin

use among ambulatory patients with nonvalvular atrial fibrillation: the

Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann

Intern Med. 1999;131(12):927-34.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,

et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin

in patients with atrial fibrillation. N Eng J Med. 2011;365(11):981-92.

Hacke W. Rivaroxaban effective for secondary stroke prevention in AF:

ROCKET AF analysis. [Access in 2011 July 25]. Available from: http://www.

theheart.org/article/1232007.

Jackson JM, Thomas SJ. Valvular heart disease. In: Kaplan JA. Cardiac anesthesia, 3rd Ed. Phidadelfia: WB Saunders, 1999;644-650.

Kilicaslan F, Verma A, Saad E et al.. Efficacy of catheter ablation of atrial fibrillation in patients with hyperthrophic obstructive cardiomyopathy. Heart Rhythm. 2006;3:275-80.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk

stratification for predicting stroke and thromboembolism in atrial fibrillation

using a novel risk factor-based approach: the Euro Heart Survey on atrial

fibrillation. Chest. 2010;137(2):263-72.

Maron BJ, Dearani JA, Ommen SR et al. The case for surgery in obstructive hypertrofic cardiomyopathy. J Am Coll Cardiol 2004;44:2044-2053.

Maron BJ, McKenna WJ, Danielson G, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/ European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J. 2003; 24(21):1965-91.

Maron BJ. Hypertrophic cardiomyopathy - a systematic review. JAMA. 2002; 287(10):1308-20.

Maron BJ, McKenna WJ, Danielson GK et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hyperthrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-713.

Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et

al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis

of patients undergoing cardioversion. Circulation. 2011;123(2):131-6.

Olivotto I, Cecchi F, Casey AS, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hyperthrophic cardiomyopathy. Circulation 2001;104:2517-2524.

Rickers C, Wilke N, Jarosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005; 112(6):855-66.

Sherman DG. Stroke prevention in atrial fibrillation: pharmacological rate

versus rhythm control. Stroke. 2007;38(2 Suppl):615-7.

Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB,

et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management

(AFFIRM) Investigators. A comparison of rate control and rhythm control

in patients with atrial fibrillation. N Eng J Med. 2002;347(23):1825-33.

Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35(1):36-44.

Stewart RA. Clinical trials of direct thrombin and factor Xa inhibitors in atrial

fibrillation. Curr Opin Cardiol. 2011;26(4):294-9.

Apontamentos

  • Não há apontamentos.